Abstracts tagged "pediatric rheumatology and treatment"

Abstract Number: 248 • 2017 ACR/ARHP Annual Meeting
Validation of Objective Quantification System for Disease Progression in Patients with Juvenile Idiopathic Arthritis
Olga Kubassova¹, N Tzaribachev², Romiesa Hagoug³ and Mikael Boesen⁴, ¹R&D, Image Analysis Group, London, England, ²University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, ³Imaging, Image Analysis Group, London, United Kingdom, ⁴Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiskberg, Denmark
Background/Purpose: Imaging as outcome measure has been studied and extensively used in the assessment of treatment for adult patients with rheumatoid arthritis (RA)1. In children…
Abstract Number: 2281 • 2017 ACR/ARHP Annual Meeting
Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry
Sarah Ringold¹, Fenglong Xie², Daniel B. Horton³, Melissa L. Mannion⁴, Colleen K. Correll⁵, Anne C. Dennos⁶ and Timothy Beukelman⁷, ¹Seattle Children's Hospital, Seattle, WA, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry began enrolling children with juvenile idiopathic arthritis (JIA) in July 2015. The large number of…
Abstract Number: 1365 • 2016 ACR/ARHP Annual Meeting
Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Takayuki Kishi¹, Nastaran Bayat², Michael Ward³, Adam Huber⁴, Lan Wu¹, Gulnara Mamyrova⁵, Ira Targoff⁶, William Warren-Hicks⁷, Frederick W. Miller², Lisa G. Rider⁸ and the Childhood Myositis Heterogeneity Study Group, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴IWK Health Centre, Halifax, NS, Canada, ⁵Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC, ⁶VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Social and Scientific Systems, Inc., Durham, NC, ⁸Environmental Autoimmunity Grp, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with characteristic rashes and chronic muscle inflammation. Because of its rarity, most therapeutic choices are based…
Abstract Number: 1780 • 2013 ACR/ARHP Annual Meeting
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite¹, Kristi Prather², Yuliya Lokhnygina³, Laura E. Schanberg⁴, Melissa Elder⁵, Diana Milojevic⁶, James W. Verbsky⁷, Steven J. Spalding⁸, Yukiko Kimura⁹, Lisa F. Imundo¹⁰, Marilynn G. Punaro¹¹, David D. Sherry¹², Stacey E. Tarvin¹³, Lawrence S. Zemel¹⁴, James D. Birmingham¹⁵, Beth S. Gottlieb¹⁶, Michael L. Miller¹⁷, Kathleen M. O'Neil¹⁸, Natasha M. Ruth¹⁹, Carol A. Wallace²⁰, Nora G. Singer²¹ and Christy I. Sandborg²², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Statistics, Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatrics, University of Florida, Gainesville, HI, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁸Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹⁴Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, ¹⁵Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ¹⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁷Rheumatology, Childrens Memorial Hospital, Chicago, IL, ¹⁸Division of Pediatric Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²⁰University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²²Pediatric Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT) is a multicenter controlled trial using a…
Abstract Number: 2021 • 2012 ACR/ARHP Annual Meeting
The Schedule of Administration of Canakinumab in Cryopyrin Associated Periodic Syndrome Is Driven by the Phenotype Severity Rather Than the Age
Roberta Caorsi¹, Loredana Lepore², Francesco Zulian³, Maria Alessio⁴, Achille Stabile⁵, Antonella Insalaco⁶, Martina Finetti¹, Antonella Battagliese⁴, Giorgia Martini⁷, Chiara Bibalo⁸, Alberto Martini⁹ and Marco Gattorno¹, ¹Second Division of Paediatrics, G. Gaslini Institute, Genova, Italy, ²Istituto Burlo Garofolo, Trieste, Italy, ³Department of Pediatrics, University of Padua, Padova, Italy, ⁴Department of Pediatrics,, Federico II Hospital, Napoli, Italy, ⁵DipartimentoPediatria, Policlinico Gemelli, Roma, Italy, ⁶Department of Pediatric Rheumatology, Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Department of Pediatrics,, University of Padua, Padua, Italy, ⁸Pediatrics-Univ of Trieste, Ospedale-Infantile Trieste, Trieste, Italy, ⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose: to identify the optimal regimen for the treatment with Canakinumab in CAPS patients and, in patients receiving both Anakinra and Canakinumab during their disease…
Abstract Number: 2031 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Anakinra in Patients with Deficiency of Interleukin-1 Receptor Antagonist
Gina A. Montealegre¹, Adriana Almeida de Jesus², Dawn C. Chapelle³, Paul Dancey⁴, Joost Frenkel⁵, Annet van Royen-Kerkhoff⁶, Ronit Herzog⁷, Giovanna Ciocca⁸, Rafael F. Rivas-Chacon⁸, Ann M. Reed⁹, Nicole Plass³, Ivona Aksentijevich¹⁰, Polly J. Ferguson¹¹, Suvimol C. Hill¹², Edward Cowen¹³ and Raphaela T. Goldbach-Mansky³, ¹NIAMS, Bethesda, MD, ²Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁴Health Science Centre, Memorial University of Newfoundland, St Johns, Canada, ⁵Wilhelmina Childrens Hospital, University of Utrecht, Utrecht, Netherlands, ⁶University of Utrecht, Utrecht, Netherlands, ⁷Cornell University, New York, NY, ⁸Miami Children's Hospital, Miami, FL, ⁹Rheumatology, Mayo Clinic, Rochester, MN, ¹⁰Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ¹¹Dept of Pediatrics--Rheum, University of Iowa Carver College of Medicine, Iowa City, IA, ¹²Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD, ¹³Dermatology Consultation Servce, National Cancer Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Deficiency of interleukin-1 receptor antagonist (DIRA) is a neonatal-onset autoinflammatory syndrome caused by mutations in IL1RN gene and clinically characterized by a perinatal onset…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].